Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Payables (2016 - 2025)

Historic Payables for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $19.6 million.

  • Agios Pharmaceuticals' Payables rose 1405.82% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 1405.82%. This contributed to the annual value of $16.6 million for FY2024, which is 7017.38% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Payables stood at $19.6 million, which was up 1405.82% from $17.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Payables' 5-year high stood at $51.2 million during Q1 2021, with a 5-year trough of $7.7 million in Q2 2021.
  • For the 5-year period, Agios Pharmaceuticals' Payables averaged around $14.9 million, with its median value being $11.6 million (2023).
  • Its Payables has fluctuated over the past 5 years, first surged by 17382.26% in 2021, then plummeted by 7745.0% in 2022.
  • Agios Pharmaceuticals' Payables (Quarter) stood at $16.7 million in 2021, then increased by 11.47% to $18.6 million in 2022, then crashed by 47.46% to $9.8 million in 2023, then surged by 70.17% to $16.6 million in 2024, then rose by 17.48% to $19.6 million in 2025.
  • Its Payables stands at $19.6 million for Q3 2025, versus $17.5 million for Q2 2025 and $13.7 million for Q1 2025.